Press Releases

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases, announced the initiation of dosing in a Phase 1 clinical trial evaluating TERN-501, a selective thyroid hormone receptor beta (THR-β) agonist with high metabolic stability, enhanced liver distribution and greater selectivity for THR-β

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors, together with Yale Cancer Center, a National Cancer Institute-designated comprehensive cancer center, today announced a research collaboration for the assessment of the potential of Allocetra™ to enhance the activity of checkpoint inhibitors in solid tumors.  Allocetra™ is a macrophage-reprogramming immun

The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), and Stelis Biopharma Pvt. Ltd., the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce, and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against coronavirus sufficient to vaccinate 100 million people. The agreement between RDIF and Stelis Biopharma was reached under the aegis of Enso Healthcare LLP (part of Enso Group)

Artelo Biosciences, Inc., a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, announced that it has been accepted into the first round of the Alderley Park Oncology Development Program, a UK national program designed to offer advice, guidance, and financial support to develop and progress innovative oncology projects. The Alderley Park Oncology Development Program is funded

ONK Therapeutics Ltd, an innovative cell therapy company focused on engineered natural killer (NK) cell therapies, announced it has entered into a license with the US National Institutes for Health (NIH) which provides rights to make and use a clinically-validated GMP-grade feeder cell line that will enable robust natural killer (NK) cell expansion, supporting scale-up of the company’s manufacturing process. Engineered NK cell therapies are now emerging as an exciting cell the

Anima Biotech, the leader in the discovery of small molecule drugs that selectively control mRNA translation, announced that the company has entered into a strategic collaboration with Takeda Pharmaceutical Company Limited (“Takeda”) to discover and develop a new class of medicines for genetically-defined neurological diseases. Under the terms of the agreement, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators agai

Hoth Therapeutics, Inc., a biopharmaceutical company, today announced entering into a Research Agreement with the University of Cincinnati Research Institute ("UCRI") to perform critical antimicrobial characterization studies with HT-006 as part of the streamlined drug development plan. HT-006 is a novel antibiotic under development as a potential treatment for multi-drug resistant bacterial lung infections, such as hospital-acquired pneumonia (HAP), cystic fibrosis (CF), chronic ob

WuXi Biologics, a global company with leading open-access biologics technology platforms, today announced it has entered into a purchase agreement with CBC Group ("CBC"), a healthcare-dedicated investment firm, and other companies including Ming Bioventures under which WuXi Bio will acquire over 90% interest of CMAB Biopharma Group ("CMAB"). The transaction is expected to close in the second quarter of 2021. As a Contract Development and Manufacturing Organizatio

Visus Therapeutics Inc. (the “Company”), a clinical-stage pharmaceutical company in pursuit of developing the world’s first presbyopia-correcting eye drop with the potential to last a minimum of eight hours, announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug Application (IND) to proceed with the clinical development program for BRIMOCHOL™, the company’s lead investigational asset. BRIMOCHOL, a prop

Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced a collaboration to enhance identification of patients with any solid tumor harboring an NRG1 fusion who may be eligible for enrollment in the Phase 2 CRESTONE study. NeoGenomics is a leading pro